Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Sigma, Vitatron Collection II Pacemaker Launch Expected Shortly

This article was originally published in The Gray Sheet

Executive Summary

Medtronic expects to begin shipments of the Sigma line of pacemakers in early September, a move that will trigger a phase-out process for its Prodigy, Preva and Prevail bradycardia devices, the company says.

You may also be interested in...



Vitatron Pacing Line Could Hit U.S. In 12 Months Following European Release

U.S. release of 14 Vitatron pacemaker models is expected over the next 12-15 months, the Medtronic subsidiary said following the April 21 launch of the devices in European markets.

Medtronic's International Release Of Sigma Line Balances Pacing Offerings

Medtronic is filling out its pacemaker offerings with the international roll-out of its Sigma line of "basic" pacemakers in order to meet "the various and economic needs of patients around the world," the company announced Feb. 11. Shipments of the new line began in late January.

Organon And Henlius Complete Phase III For Denosumab

Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel